drugset / Trial / NCT00736658

AZD1386 Japanese Multiple Ascending Dosing Study

NCT00736658

Phase 1 Completed 32 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a single centre, double-blind, randomised, parallel group, placebo controlled study to assess the safety, tolerability and pharmacokinetics of AZD1386 when given as multiple doses to 32 (24 healthy young and 8 healthy elderly) Japanese subjects. For young healthy subjects (aged ≥20 to ≤45 inclusive) 3 consecutive multiple ascending dose panels are planned. For elderly healthy subjects (aged ≥65 to≤80 inclusive) 1 multiple dose panel is planned.

Timeline

Start
2008-06
Primary completion
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1386 Small molecule Oral

Indications